具核梭杆菌在口腔黏膜癌变中的作用与机制

doi:10.13701/j.cnki.kqyxyj.2024.05.001

摘要/Abstract

摘要： 口腔黏膜癌变是一种严重的健康问题,其发生、发展涉及多种因素。近年来,具核梭杆菌作为口腔微生物群落的一部分,被视为在多种癌症中发挥重要作用的感染性因素之一。本综述旨在全面探讨具核梭杆菌在口腔黏膜癌变中的作用和机制。通过分析临床和分子生物学研究,发现具核梭杆菌与口腔潜在恶性疾患和口腔鳞状细胞癌的发生及发展密切相关。具体来说,该菌种可以调控肿瘤免疫微环境,促进细胞增殖和侵袭,以及激活免疫检查点。此外,具核梭杆菌还可能作为口腔癌的生物标志物和治疗目标。然而,该领域的研究仍面临样本数量不足、患者特异性强以及多学科交叉合作的挑战。未来研究需要进一步揭示其作用机制,并探索其在口腔癌预防和治疗中的潜在应用。

关键词: 具核梭杆菌, 口腔黏膜癌变, 肿瘤免疫微环境, 细胞增殖, 细胞侵袭, 免疫检查点

Abstract: Oral mucosal carcinogenesis is a serious health issue involving multiple factors in its onset and progression. In recent years, fusobacterium nucleatum (F.nucleatum), as a part of the oral microbiota, has been considered as one of the infectious agents playing a significant role in various cancers. This review aims to comprehensively explore the role and mechanisms of F.nucleatum in oral mucosal carcinogenesis. Through the analysis of clinical and molecular biology studies, we found that F.nucleatum is closely related to the occurrence and development of oral potentially malignant disorders (OPMD) and oral squamous cell carcinoma (OSCC). Specifically, this bacterium can modulate the tumor immune microenvironment, promote cell proliferation and invasion, and activate immune checkpoints. Additionally, F.nucleatum may serve as a biomarker and therapeutic target for oral cancer. However, research in this field still faces challenges such as insufficient sample size, strong patient specificity, and the need for multidisciplinary collaboration. Future studies are needed to further reveal its mechanisms and explore its potential applications in the prevention and treatment of oral cancer.

Key words: Fusobacterium nucleatum, oral mucosal carcinogenesis, tumor immune microenvironment, cell proliferation, cell invasion, immune checkpoints

曲别芳芳, 江潞. 具核梭杆菌在口腔黏膜癌变中的作用与机制[J]. 口腔医学研究, 2024, 40(5): 379-384.

QUBIE Fangfang, JIANG Lu. Role and Mechanism of Fusobacterium Nucleatum in Oral Mucosal Carcinogenesis[J]. Journal of Oral Science Research, 2024, 40(5): 379-384.

参考文献

[1] Stokowa-Sołtys K, Wojtkowiak K, Jagiełło K. Fusobacterium nucleatum-Friend or foe? [J]. J Inorg Biochem, 2021, 224: 111586.
[2] Wu J, Li Q, Fu X. Fusobacterium nucleatum contributes to the carcinogenesis of colorectal cancer by inducing inflammation and suppressing host immunity [J]. Transl Oncol, 2019, 12(6): 846-851.
[3] Hsieh YY, Tung SY, Pan HY, et al. Fusobacterium nucleatum colonization is associated with decreased survival of helicobacter pylori-positive gastric cancer patients [J]. World J Gastroenterol, 2021, 27(42): 7311-7323.
[4] Van der Merwe M, Van Niekerk G, Botha A, et al. The onco-immunological implications of Fusobacterium nucleatum in breast cancer [J]. Immunol Lett, 2021, 232: 60-66.
[5] 古建昌,宋继武,刘云,等.1990~2019年我国口腔癌疾病负担及其变化趋势分析[J].中国预防医学杂志,2022,23(6): 457-461.
[6] Mcilvanna E, Linden GJ, Craig SG, et al. Fusobacterium nucleatum and oral cancer: a critical review [J]. BMC Cancer, 2021, 21(1): 1212.
[7] Warnakulasuriya S, Kujan O, Aguirre-Urizar JM, et al. Oral potentially malignant disorders: A consensus report from an international seminar on nomenclature and classification, convened by the WHO Collaborating Centre for Oral Cancer [J]. Oral Dis, 2021, 27(8): 1862-1880.
[8] Bouaoud J, Bossi P, Elkabets M, et al. Unmet needs and perspectives in oral cancer prevention [J]. Cancers (Basel), 2022, 14(7):1815.
[9] Decsi G, Soki J, Pap B, et al. Chicken or the egg: Microbial alterations in biopsy samples of patients with oral potentially malignant disorders [J]. Pathol Oncol Res, 2019, 25(3): 1023-1033.
[10] Bronzato JD, Bomfim RA, Edwards DH, et al. Detection of Fusobacterium in oral and head and neck cancer samples: A systematic review and meta-analysis [J]. Arch Oral Biol, 2020, 112: 104669.
[11] Yang CY, Yeh YM, Yu HY, et al. Oral microbiota community dynamics associated with oral squamous cell carcinoma staging [J]. Front Microbiol, 2018, 9: 862.
[12] Ganly I, Yang L, Giese RA, et al. Periodontal pathogens are a risk factor of oral cavity squamous cell carcinoma, independent of tobacco and alcohol and human papillomavirus [J]. Int J Cancer, 2019, 145(3): 775-784.
[13] Zhang S, Li C, Zhang Z, et al. Analysis of differentially expressed genes in oral epithelial cells infected with Fusobacterium nucleatum for revealing genes associated with oral cancer [J]. J Cell Mol Med, 2021, 25(2): 892-904.
[14] Binder Gallimidi A, Fischman S, Revach B, et al. Periodontal pathogens Porphyromonas gingivalis and Fusobacterium nucleatum promote tumor progression in an oral-specific chemical carcinogenesis model [J]. Oncotarget, 2015, 6(26): 22613-22623.
[15] Stashenko P, Yost S, Choi Y, et al. The oral mouse microbiome promotes tumorigenesis in oral squamous cell carcinoma [J]. mSystems, 2019, 4(4):e00323-19.
[16] Lv B, Wang Y, Ma D, et al. Immunotherapy: Reshape the tumor immune microenvironment [J]. Front Immunol, 2022, 13: 844142.
[17] Parhi L, Alon-Maimon T, Sol A, et al. Breast cancer colonization by Fusobacterium nucleatum accelerates tumor growth and metastatic progression [J]. Nat Commun, 2020, 11(1): 3259.
[18] Yang L, Wang G, Xia H. Molecular mechanism for impaired suppressive function of Tregs in autoimmune diseases: A summary of cell-intrinsic and cell-extrinsic factors [J]. J Cell Mol Med, 2020, 24(19): 11056-11063.
[19] Zhang N, Liu Y, Yang H, et al. Clinical significance of Fusobacterium nucleatum infection and regulatory T cell enrichment in esophageal squamous cell carcinoma [J]. Pathol Oncol Res, 2021, 27: 1609846.
[20] Karpiński TM. Role of oral microbiota in cancer development [J]. Microorganisms, 2019, 7(1):20.
[21] Tam K, Schoppy DW, Shin JH, et al. Assessing the impact of targeting CEACAM1 in head and neck squamous cell carcinoma [J]. Otolaryngol Head Neck Surg, 2018, 159(1): 76-84.
[22] Chiamulera MMA, Zancan CB, Remor AP, et al. Salivary cytokines as biomarkers of oral cancer: a systematic review and meta-analysis [J]. BMC Cancer, 2021, 21(1): 205.
[23] Sharma BR, Kanneganti TD. NLRP3 inflammasome in cancer and metabolic diseases [J]. Nat Immunol, 2021, 22(5): 550-559.
[24] Wang H, Luo Q, Feng X, et al. NLRP3 promotes tumor growth and metastasis in human oral squamous cell carcinoma [J]. BMC Cancer, 2018, 18(1): 500.
[25] Lee CH, Chang JS, Syu SH, et al. IL-1β promotes malignant transformation and tumor aggressiveness in oral cancer [J]. J Cell Physiol, 2015, 230(4): 875-884.
[26] Radhika T, Jeddy N, Nithya S, et al. Salivary biomarkers in oral squamous cell carcinoma-An insight [J]. J Oral Biol Craniofac Res, 2016, 6(Suppl 1): S51-S54.
[27] Geng F, Zhang Y, Lu Z, et al. Fusobacterium nucleatum caused DNA damage and promoted cell proliferation by the Ku70/p53 pathway in oral cancer cells [J]. DNA Cell Biol, 2020, 39(1): 144-151.
[28] Yao Y, Shen X, Zhou M, et al. Periodontal pathogens promote oral squamous cell carcinoma by regulating ATR and NLRP3 inflammasome [J]. Front Oncol, 2021, 11: 722797.
[29] Hsueh CY, Lau HC, Huang Q, et al. Fusobacterium nucleatum impairs DNA mismatch repair and stability in patients with squamous cell carcinoma of the head and neck [J]. Cancer, 2022, 128(17): 3170-3184.
[30] Chen Z, Wong PY, Ng CWK, et al. The intersection between oral microbiota, host gene methylation and patient outcomes in head and neck squamous cell carcinoma [J]. Cancers (Basel), 2020, 12(11):3425.
[31] Zhang N, Ng AS, Cai S, et al. Novel therapeutic strategies: targeting epithelial-mesenchymal transition in colorectal cancer [J]. Lancet Oncol, 2021, 22(8): e358-e368.
[32] Shah AM, Jain K, Desai RS, et al. The role of increased connective tissue growth factor in the pathogenesis of oral submucous fibrosis and its malignant transformation-An immunohistochemical study [J]. Head Neck Pathol, 2021, 15(3): 817-830.
[33] St John MA. Inflammatory mediators drive metastasis and drug resistance in head and neck squamous cell carcinoma [J]. Laryngoscope, 2015, 125 Suppl 3: S1-S11.
[34] Abdulkareem AA, Shelton RM, Landini G, et al. Periodontal pathogens promote epithelial-mesenchymal transition in oral squamous carcinoma cells in vitro [J]. Cell Adh Migr, 2018, 12(2): 127-137.
[35] Zhang S, Li C, Liu J, et al. Fusobacterium nucleatum promotes epithelial-mesenchymal transiton through regulation of the lncRNA miR4435-2HG/miR-296-5p/Akt2/SNAI1 signaling pathway [J]. FEBS J, 2020, 287(18): 4032-4047.
[36] Saitoh M. Involvement of partial EMT in cancer progression [J]. J Biochem, 2018, 164(4): 257-264.
[37] Shao W, Fujiwara N, Mouri Y, et al. Conversion from epithelial to partial-EMT phenotype by Fusobacterium nucleatum infection promotes invasion of oral cancer cells [J]. Sci Rep, 2021, 11(1): 14943.
[38] Da J, Wang X, Li L, et al. Fusobacterium nucleatum promotes cisplatin-resistance and migration of oral squamous carcinoma cells by up-regulating wnt5a-mediated NFATc3 expression [J]. Tohoku J Exp Med, 2021, 253(4): 249-259.
[39] Harrandah AM, Chukkapalli SS, Bhattacharyya I, et al. Fusobacteria modulate oral carcinogenesis and promote cancer progression [J]. J Oral Microbiol, 2020, 13(1): 1849493.
[40] Dong Y, Wang Z, Mao F, et al. PD-1 blockade prevents the progression of oral carcinogenesis [J]. Carcinogenesis, 2021, 42(6): 891-902.
[41] Gao Y, Zou T, Xu P, et al. Fusobacterium nucleatum stimulates cell proliferation and promotes PD-L1 expression via IFIT1-related signal in colorectal cancer [J]. Neoplasia, 2023, 35: 100850.
[42] Gao Y, Bi D, Xie R, et al. Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer [J]. Signal Transduct Target Ther, 2021, 6(1): 398.
[43] 王蓉,姚晓文,周玉霞,等.免疫检查点TIGIT在肿瘤治疗中的最新研究进展[J].河北医学,2023,29(1):172-176.
[44] Guevarra LA Jr, Afable ACF, Belza PJO, et al. Immunogenicity of a Fap2 peptide mimotope of Fusobacterium nucleatum and its potential use in the diagnosis of colorectal cancer [J]. Infect Agent Cancer, 2018, 13: 11.
[45] Simonetti O, Lucarini G, Rubini C, et al. Correlation between immunohistochemical staining of CEACAM1 and clinicopathological findings in oral pre-neoplastic lesions and squamous cell carcinoma [J]. Med Mol Morphol, 2018, 51(1): 41-47.
[46] Gur C, Maalouf N, Shhadeh A, et al. Fusobacterium nucleatum supresses anti-tumor immunity by activating CEACAM1 [J]. Oncoimmunology, 2019, 8(6): e1581531.
[47] Neuzillet C, Marchais M, Vacher S, et al. Prognostic value of intratumoral Fusobacterium nucleatum and association with immune-related gene expression in oral squamous cell carcinoma patients [J]. Sci Rep, 2021, 11(1): 7870.
[48] Bullman S, Pedamallu CS, Sicinska E, et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer [J]. Science, 2017, 358(6369): 1443-1448.
[49] Dong J, Li Y, Xiao H, et al. Oral microbiota affects the efficacy and prognosis of radiotherapy for colorectal cancer in mouse models [J]. Cell Rep, 2021, 37(4): 109886.
[50] Zheng DW, Dong X, Pan P, et al. Phage-guided modulation of the gut microbiota of mouse models of colorectal cancer augments their responses to chemotherapy [J]. Nat Biomed Eng, 2019, 3(9): 717-728.
[51] Xu SB, Wang MY, Shi XZ, et al. Influence of PD-1/PD-L1 on immune microenvironment in oral leukoplakia and oral squamous cell carcinoma [J]. Oral Dis, 2023, 29(8):3268-3277.